Pharmacokinetic Model-Driven Remifentanil Administration in the Morbidly Obese: The `Critical Weight' and the `Fictitious Height', a Possible Solution to an Unsolved Problem?

By Colla L. La  

Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. : 397-398

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients

By >  

Clinical Pharmacokinetics, Vol. 50, Iss. 11, 2011-11 ,pp. : 739-750

Adis International

Access to resources Recommend Favorite

Allometric or Lean Body Mass Scaling of Propofol Pharmacokinetics: Towards Simplifying Parameter Sets for Target-Controlled Infusions

By >  

Clinical Pharmacokinetics, Vol. 51, Iss. 3, 2012-03 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Low-dose somatropin may augment body fat loss and preserve lean body mass in patients with obesity

By  

Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children

By Krekels Elke H.J.   DeJongh Joost   van Lingen Richard A.  

Clinical Pharmacokinetics, Vol. 50, Iss. 1, 2011-01 ,pp. : 51-63

Adis International

Access to resources Recommend Favorite